MicroPort CardioFlow Medtech Future Growth
Future criteria checks 5/6
MicroPort CardioFlow Medtech is forecast to grow earnings and revenue by 98.6% and 21.4% per annum respectively. EPS is expected to grow by 98.7% per annum. Return on equity is forecast to be 4% in 3 years.
Key information
98.6%
Earnings growth rate
98.7%
EPS growth rate
| Medical Equipment earnings growth | 35.1% |
| Revenue growth rate | 21.4% |
| Future return on equity | 4.0% |
| Analyst coverage | Low |
| Last updated | 21 Jun 2024 |
Recent future growth updates
Recent updates
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 19
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 770 | 99 | -1 | 23 | 2 |
| 12/31/2025 | 567 | -17 | -93 | -88 | 2 |
| 12/31/2024 | 449 | -169 | -215 | -230 | 2 |
| 12/31/2023 | 336 | -472 | -237 | -207 | N/A |
| 9/30/2023 | 319 | -491 | -250 | -216 | N/A |
| 6/30/2023 | 303 | -511 | -263 | -226 | N/A |
| 3/31/2023 | 277 | -483 | -247 | -204 | N/A |
| 12/31/2022 | 251 | -454 | -232 | -183 | N/A |
| 9/30/2022 | 245 | -345 | -270 | -191 | N/A |
| 6/30/2022 | 239 | -236 | -309 | -199 | N/A |
| 3/31/2022 | 220 | -209 | -290 | -180 | N/A |
| 12/31/2021 | 201 | -183 | -270 | -162 | N/A |
| 9/30/2021 | 176 | -265 | N/A | N/A | N/A |
| 6/30/2021 | 151 | -346 | N/A | N/A | N/A |
| 3/31/2021 | 128 | -372 | N/A | N/A | N/A |
| 12/31/2020 | 104 | -398 | -168 | -110 | N/A |
| 12/31/2019 | 22 | -145 | -191 | -143 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2160 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 2160 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2160 is expected to become profitable in the next 3 years.
Revenue vs Market: 2160's revenue (21.4% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2160's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2160's Return on Equity is forecast to be low in 3 years time (4%).